CTOs on the Move

Infinity Pharmaceuticals

www.infi.com

 
Infinity Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.infi.com
  • 780 Memorial Dr
    Cambridge, MA USA 02139
  • Phone: 617.453.1000

Executives

Name Title Contact Details

Funding

Infinity Pharmaceuticals raised $20M on 01/09/2020
Infinity Pharmaceuticals raised $92M on 02/12/2021

Similar Companies

Explora BioLabs

Explora BioLabs is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rainin Instrument

Rainin Instrument is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Selventa

Selventa is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Santurus

Santurus is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, apitegromab (SRK-015), a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA. We are currently evaluating apitegromab in our TOPAZ Phase 2 proof-of-concept trial in patients with later-onset (Type 2 and Type 3) SMA. Positive six-month interim analysis results were announced in October 2020 and top-line data for the full 12-month treatment period are anticipated in the second quarter of 2021. In addition, we are conducting our DRAGON Phase 1 proof-of-concept trial for SRK-181, a highly specific inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors. We believe SRK-181 has the potential to overcome resistance and meaningfully increase the number of patients who may benefit from checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies. Utilizing our proprietary platform, we are creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia.